Trial Profile

A Phase I, Clinical Study to Evaluate the Ii-Key Vaccine in China

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 06 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Coronavirus vaccine Generex Biotechnology (Primary)
Indications COVID 2019 infections
Focus Adverse reactions

Most Recent Events

06 Jan 2021 New trial record
31 Dec 2020 According to a Generex Biotechnology Corporation media release, the company has initiated discussions with Chinese partners on the technology transfer, GMP production, and regulatory filings with the NMPA for the Phase I, II and III clinical programs in China.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com